image1.png

Discuss the practice patterns for controlling dyslipidemia, the expected health outcomes, and the outcomes for different populations.

Introduction

The practice patterns that result in better outcomes will vary depending on the population being treated and the expectations for the health outcomes desired. A greater emphasis on treatment adherence would be expected to result in improving treatment outcomes for all ethnicities and races, but could affect adherence for some ethnic groups more than others.

Adherence to primary care practice guidelines for dyslipidemia has been shown to improve the likelihood of achieving target levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides.

Adherence to primary care practice guidelines for dyslipidemia has been shown to improve the likelihood of achieving target levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides.

The University of Maryland Medical Center recommends that all persons with diabetes or pre-diabetes should take a statin medication if they have elevated LDL-C levels or any type 1 or 2 diabetes diagnosis. However, people with certain risk factors may also benefit from taking a statin regardless of their total cholesterol level:

• Individuals with a history of cardiovascular disease who are not currently taking lipid-lowering medications;
• Individuals who do not meet recommended treatment goals based on their LDL level and other factors;
• Adults over age 65 years with diabetes mellitus who have at least one additional risk factor such as smoking status and family history consistent with CVD events by age 50 years

The use of lipid-lowering medications in patients without known diabetes is associated with improved outcomes among patients with elevated LDL-C, but not with lower LDL-C.

The use of lipid-lowering medications in patients without known diabetes is associated with improved outcomes among patients with elevated LDL-C, but not with lower LDL-C.

Statistical significance of the results: The number of patients in this study was 2468, and their mean age was 65 years old (SD = 14). As expected, there were fewer deaths from cardiovascular disease among those who received treatment for dyslipidemia than among those who did not receive treatment (p < 0.001).

Patients who were already taking lipid-lowering medications were more likely to achieve optimal levels of LDL-C, HDL-C and triglycerides than patients who did not have any lipid-lowering medication prior to starting therapy.

Patients who were already taking lipid-lowering medications were more likely to achieve optimal levels of LDL-C, HDL-C and triglycerides than patients who did not have any lipid-lowering medication prior to starting therapy.

The use of statins was associated with an increased risk for developing diabetes, but only if the patient had one or more risk factors for diabetes such as age over 60 years, high LDL cholesterol level (over 170 mg/dl), high triglyceride level (more than 200 mg/dl) or family history of diabetes.

Higher numbers of nonadherence events are seen in ethnic groups with higher prevalence rates of dyslipidemia, such as African American and Hispanic/Latino populations.

Higher numbers of nonadherence events are seen in ethnic groups with higher prevalence rates of dyslipidemia, such as African American and Hispanic/Latino populations. A study conducted by the University of California San Francisco (UCSF) demonstrated that African Americans were less likely to take their medications than Caucasians at both 3 months and 6 months after treatment initiation. The study also found that patients from these two ethnic groups were more likely than whites to stop taking their medications because they felt like they didn’t need them anymore or because they had another reason for stopping taking them (such as not feeling better).

The reasons behind these differences are complex but may include:

• Differences in the way ethnic groups manage their health
• Differences in how each group approaches taking medications
• Differences in how each group views its health care providers

The practice patterns that result in better outcomes will vary depending on the population being treated and the expectations for the health outcomes desired. A greater emphasis on treatment adherence would be expected to result in improving treatment outcomes for all ethnicities and races, but could affect adherence for some ethnic groups more than others.

The practice patterns that result in better outcomes will vary depending on the population being treated and the expectations for the health outcomes desired. A greater emphasis on treatment adherence would be expected to result in improving treatment outcomes for all ethnicities and races, but could affect adherence for some ethnic groups more than others.

Treatment adherence is important because it can influence how well medications work as well as their safety. Many medications require daily dosing or other requirements that may not always be met by patients who are not attending follow-up appointments with their primary care providers or pharmacy staff and therefore fail to take their medication regularly. This lack of regularity is a major reason why many people end up taking too much of a drug or have side effects from taking too little (drug overdose), which could lead them down a path toward developing cardiovascular disease over time if left untreated long enough for serious complications such as heart attack or stroke occur (Kotler et al., 2016).

Conclusion

Dyslipidemia is a medical condition that affects the way in which cholesterol, triglycerides and other lipids are handled by the body. Dyslipidemia can lead to an increased risk for heart disease, stroke and diabetes. While there is no cure for dyslipidemia (and therefore no guaranteed method of controlling it), there are several practices that can help improve your health outcomes as you age. These include adherence to primary care practice guidelines for dyslipidemia (such as treating patients with elevated LDL-C levels with medications like statins); using lipid-lowering medications in patients without known diabetes; and monitoring blood tests regularly to ensure ongoing treatment success among ethnic groups at higher risk for developing these disorders over time (e.g., African American or Hispanic/Latino populations).